Monthly Archives: May 2018

Youngevity Q1 Sales Up 11% To $43 Million

Youngevity International, Inc. (NASDAQ:YGYI), a leading omni-direct lifestyle company, today reported financial results for the first quarter ended March 31, 2018.
2018 First Quarter Highlights:

Revenues increased 11.0% over the prior year to $43.0 million
Gross Profit increased 14.4% to $25.0 million compared to the prior year
Adjusted EBITDA increased to $1.5 million compared to negative $1.2 million in the prior year
The Coffee Segment posted 39.9% revenue growth over prior year

Steve Wallach, Chairman and CEO of Youngevity stated, “We are pleased to see revenue growth for both segments in the first quarter.  Our international markets are beginning to contribute more significantly to overall revenue lead by top line growth coming from Asia.  We believe this overall growth is sustainable in the coming quarters.”
Dave Briskie, President and CFO of Youngevity said, “We have been focused on the fundamentals as we entered 2018.  We feel we made significant progress by improving adjusted EBITDA and strengthening our balance sheet as well.  The recent financing and debt conversion contributed significantly to the improvement in our Stockholders’ Equity and will help reduce borrowing costs in the coming quarters.”
FIRST QUARTER 2018 FINANCIAL RESULTS
Revenues increased 11.0% to $42,994,000 in the current period as compared to $38,733,000 for the same period last year. We

Read more...

Rodan + Fields Faces A Second Lawsuit Over Eyelash Enhancer

CBS NEWS– Skincare products company Rodan + Fields is facing a second federal class action lawsuit alleging that the multi-level marketing company failed to disclose the harmful side effects of a key ingredient in its Lash Boost eye serum which it claims gives users “the appearance of lush, longer-looking lashes.”
As in an April 13 lawsuit, the new case singles out isopropyl cloprostenate, a type of medication called a prostaglandin analog that’s used to treat glaucoma and other eye diseases. It has been linked to dry eye, eye irritation, eye inflammation, eye redness, and macular edema, the latest lawsuit says, and had the lead plaintiff, Melissa Ryan of San Diego, known about the “documented health risks” of the chemical, she wouldn’t have purchased Lash Boost or would have paid less for it.
“R+F (Rodan + Fields) further claims that for ‘best results,’ use Lash Boost daily for 8 weeks, which would likely require a customer to buy at least two tubes of the costly (retail price of about $150) Lash Boost and further exposing the consumer to potential serious health effects,” according to the court filing.
Attorneys for Ryan and a spokesperson for Rodan + Fields couldn’t immediately be reached for comment. San Francisco-based

Read more...